The oral selective SGLT2 inhibitor ipragliflozin has been shown to improve hyperglycemia, dyslipidemia, liver steatosis, oxidative stress, inflammation, and liver injury in T2DM animal models [25–27]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.